PL1761520T3 - Inhibitory kinazy - Google Patents

Inhibitory kinazy

Info

Publication number
PL1761520T3
PL1761520T3 PL05766569T PL05766569T PL1761520T3 PL 1761520 T3 PL1761520 T3 PL 1761520T3 PL 05766569 T PL05766569 T PL 05766569T PL 05766569 T PL05766569 T PL 05766569T PL 1761520 T3 PL1761520 T3 PL 1761520T3
Authority
PL
Poland
Prior art keywords
kinase inhibitors
formula
present
inhibitors
provides kinase
Prior art date
Application number
PL05766569T
Other languages
English (en)
Inventor
Dios Alfonso De
Tiechao Li
Cabrejas Luisa Maria Martin
Mark Andrew Pobanz
Chuan Shih
Yong Wang
Boyu Zhong
Jesus Andres Blas
De Uralde-Garmendia Beatriz Lopez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04380131A external-priority patent/EP1609789A1/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1761520T3 publication Critical patent/PL1761520T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05766569T 2004-06-23 2005-06-15 Inhibitory kinazy PL1761520T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP04380131A EP1609789A1 (en) 2004-06-23 2004-06-23 Ureido-pyrazole derivatives and their use as kinase inhibitors
US59253904P 2004-07-30 2004-07-30
EP04380174 2004-08-23
US62249204P 2004-10-27 2004-10-27
PCT/US2005/021148 WO2006009741A1 (en) 2004-06-23 2005-06-15 Kinase inhibitors
EP05766569A EP1761520B1 (en) 2004-06-23 2005-06-15 Kinase inhibitors

Publications (1)

Publication Number Publication Date
PL1761520T3 true PL1761520T3 (pl) 2008-12-31

Family

ID=43875180

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05766569T PL1761520T3 (pl) 2004-06-23 2005-06-15 Inhibitory kinazy

Country Status (9)

Country Link
US (1) US7767674B2 (pl)
EP (1) EP1761520B1 (pl)
AT (1) ATE400567T1 (pl)
DK (1) DK1761520T3 (pl)
ES (1) ES2308523T3 (pl)
PL (1) PL1761520T3 (pl)
PT (1) PT1761520E (pl)
SI (1) SI1761520T1 (pl)
WO (1) WO2006009741A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
JP2007532484A (ja) 2004-03-16 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
TWI325423B (en) * 2005-10-28 2010-06-01 Lilly Co Eli Kinase inhibitors
DOP2006000233A (es) * 2005-10-28 2007-06-15 Lilly Co Eli Inhibidores de cinasa
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
JP2010531887A (ja) * 2007-06-26 2010-09-30 グラクソスミスクライン エルエルシー ベンズイミダゾールチオフェンの調製方法
US8314091B2 (en) 2007-08-20 2012-11-20 Msd Oss B.V. N-benzyl,N'-arylcarbonylpiperazine derivatives
AU2009230127B2 (en) 2008-03-26 2011-12-22 Daiichi Sankyo Company, Limited Novel tetrahydroisoquinoline derivative
TW201022230A (en) * 2008-08-28 2010-06-16 Organon Nv 1-(4-ureidobenzoyl)piperazine derivatives
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
WO2010038086A2 (en) 2008-10-02 2010-04-08 Respivert Limited Novel compounds
AU2009326148B2 (en) 2008-12-11 2014-05-08 Respivert Limited p38 MAP kinase inhibitors
WO2010094956A1 (en) 2009-02-17 2010-08-26 Pulmagen Therapeutics (Inflammation) Limited. Triazolopyridine derivatives as p38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
JP2013506691A (ja) * 2009-10-02 2013-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド ホスファチジルイノシトール3−キナーゼのピラゾール阻害薬
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
RU2623734C9 (ru) 2011-12-09 2017-09-18 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибиторы киназы
KR101994381B1 (ko) 2011-12-09 2019-06-28 키에시 파르마슈티시 엣스. 피. 에이. 키나아제 억제제
US9150570B2 (en) * 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
BR112015029970A2 (pt) 2013-06-06 2017-07-25 Chiesi Farm Spa inibidores de cinase
AR107163A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
WO2017108737A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
RU2731095C2 (ru) 2016-03-17 2020-08-28 Ф. Хоффманн-Ля Рош Аг Производное 5-этил-4-метил-пиразол-3-карбоксамида, обладающее активностью агониста taar
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
JP4820488B2 (ja) * 1999-03-12 2011-11-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬として有用な化合物
ATE386030T1 (de) * 2002-02-25 2008-03-15 Boehringer Ingelheim Pharma 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
GB0320244D0 (en) * 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
WO2004101529A1 (ja) 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途

Also Published As

Publication number Publication date
EP1761520A1 (en) 2007-03-14
ATE400567T1 (de) 2008-07-15
PT1761520E (pt) 2008-09-15
EP1761520B1 (en) 2008-07-09
US7767674B2 (en) 2010-08-03
SI1761520T1 (sl) 2008-10-31
US20080306068A1 (en) 2008-12-11
DK1761520T3 (da) 2008-10-27
WO2006009741A1 (en) 2006-01-26
ES2308523T3 (es) 2008-12-01

Similar Documents

Publication Publication Date Title
SI1761520T1 (sl) Inhibitorji kinaze
MY143516A (en) Kinase inhibitors
TW200640924A (en) VEGF-R2 inhibitors and methods
IL163781A0 (en) Purine derivatives as kinase inhibitors
IL163777A0 (en) Kinase inhibitors
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MX2009007077A (es) Analogos de ciclopamina.
TW200624426A (en) BACE inhibitors
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
HK1115590A1 (en) Triazolophthalazines
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
TN2011000293A1 (en) Protein kinase inhibitors
TNSN08191A1 (en) Kinase inhibitors
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
JO2822B1 (en) Inhibitors of the enzyme kinase P70 S6 and AKT
MX2008001538A (es) Aril piridinas y metodos para su uso.
MX2010010406A (es) Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
ATE548364T1 (de) Aminopyrazolkinasehemmer
EP1891082A4 (en) NEW INHIBITORS OF PYRUVATE KINASE AS THERAPEUTIC AGENTS AGAINST CANCER
DOP2005000117A (es) Inhibidores de quinasa